Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New imaging agent could sharpen brain tumor detection

NCT ID NCT06474533

Diagnosis Sponsor: Thomas Hope Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 2 times

Summary

This study tests a radioactive tracer called FET that lights up brain tumor cells on a PET scan. Researchers want to see if FET can better detect whether a brain tumor has come back after treatment, and help tell high-grade from low-grade tumors. About 199 people with known or suspected brain tumors will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 199 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults and children over the age of 3 with intracranial neoplasms (glial or metastatic disease).

Ages

4 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Presence or suspicion of intracranial neoplasm in two populations: * Population 1: Participants after primary treatment (radiation therapy and/or surgery) with suspicion of recurrence on MRI. * Three sub-populations will be considered: * Recurrent metastatic lesions. * Recurrent high-grade gliomas (Grades 3 and 4). * Recurrent low-grade gliomas (Grade 2). * Population 2: Participants prior to primary treatment with planned biopsy or surgical resection. * Age \> 3 years. Participants in other clinical trials will be eligible for this study including patients undergoing surgery guided by 5-aminolevulinic acid. Exclusion Criteria: * Participants with known incompatibility to PET or Computerized tomography (CT)/magnetic resonance imaging (MRI) scans. * Participants unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for study participation. * Sedation or anesthesia can be used for participants who cannot tolerate the exam.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intracranial neoplasm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer brain neoplasm low grade glioma malignant glioma metastatic malignant neoplasm in the brain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intracranial neoplasm

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.